Patients with rheumatoid arthritis (RA) who require a change in therapy from anti–tumor necrosis factor inhibitor (anti-TNF) treatments to biologics with a different mechanism of action (MOA) had higher treatment persistence and lower healthcare costs than patients who cycled anti-TNF drugs, resulting in lower healthcare costs per persistent patient among the MOA switchers, a recent study finds.
Patients with rheumatoid arthritis (RA) who require a change in therapy from anti—tumor necrosis factor inhibitor (anti-TNF) treatments to biologics with a different mechanism of action (MOA) had higher treatment persistence and lower healthcare costs than patients who cycled anti-TNF drugs, resulting in lower healthcare costs per persistent patient among the MOA switchers, a recent study finds.
“MOA switching is associated with economic and clinical advantages for RA patients and their health plans when a change in therapy is required,” Benjamin Chastek, MS, and colleagues conclude, and said that reimbursement policies requiring patients to cycle anti-TNF products before switching to a different MOA may end up resulting in suboptimal outcomes for both patients and payers. The findings were published in Advances in Therapy.
Recent RA treatment guidelines recommend that, if disease activity remains moderate or high despite monotherapy with disease-modifying antirheumatic drugs (DMARDs), patients should be switched to a drug with a different MOA earlier in the treatment paradigm. Guidelines now recommend other MOA therapies either as an alternative option to an anti-TNF drug for first-line biological therapy, or as an option for second-line therapy after failure of an anti-TNF drug instead of cycling to another anti-TNF option. Although these guidelines are supported by evidence of improved treatment persistence, clinical outcomes, and lower costs after switching to a different MOA compared with anti-TNF drug cycling, cycling remains more common than MOA switching in clinical practice.
The researchers studied claims data of patients with RA and at least 1 claim for an anti-TNF therapy (adalimumab, certolizumab pegol, etanercept, golimumab, or infliximab) between January 2012 and September 2015 who changed to another anti-TNF agent or a different MOA therapy (abatacept, tocilizumab, or tofacitinib) within 1 year.
From among a study population of 1516 patients, they identified 581 MOA switchers and 935 anti-TNF cyclers. Treatment persistence was defined as no subsequent switch or a 60-day gap in therapy for 1 year. RA-related costs included plan-paid and patient-paid amounts for inpatient, outpatient, and pharmacy claims; medication costs included index and post-index costs of anti-TNF drugs and different MOA therapies. The study did not examine outcomes for individual medications within each class.
The study found the following:
Switching to a different MOA may lower not only the non-drug healthcare costs, but also drug costs compared with anti-TNF cycling because the observed difference in mean RA-related costs was driven largely by lower targeted DMARD costs among MOA switchers versus anti-TNF cyclers. “Consistent findings for treatment persistence across different patient populations may have clinical implications for the management of RA, because greater treatment persistence and adherence have been reported to improve clinical outcomes in RA,” the researchers note.
Because RA treatment guidelines were updated after the study period, more study is needed to determine whether these recent changes to the guidelines will influence clinical practice and lead to increased use of different MOA therapies compared with anti-TNF drugs.
The research was supported by Sanofi and Regeneron Pharmaceuticals.
AMCP Posters Tackle Interchangeability and Medicaid, Factors Driving Biosimilar Access
April 24th 2024Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine biosimilar plays into Medicaid budgets and the top factors driving access to biosimilars.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
What Clinicians Need to Know About Using Biosimilars to Treat IBD
April 13th 2024A review article, intended to act as a guide for clinicians, summarizes the available infliximab and adalimumab biosimilars for treating inflammatory bowel disease (IBD) as well as others that are coming down the pipeline.